

**18TH INDUSTRY/ACADEMIA
NEXT GENERATION PRECISION
ONCOLOGY SYMPOSIUM**

SPEAKER BIOGRAPHIES

SEPTEMBER 15, 2022

THE ALEXANDRIA AT TORREY PINES
LA JOLLA, CA



Ida Deichaite, PhD

*Director, Industry Relations, Moores Cancer Center
Assistant Adjunct Professor,
Radiation Medicine and Applied Sciences
UC San Diego*

Dr. Ida Deichaite oversees the translational aspects of oncology at UC San Diego Moores Cancer Center, turning innovation into commercial applications. Her successful partnering with pharma includes overseeing strategy and execution of translational alliances between academia and industry.

Dr. Ida Deichaite is an Assistant Adjunct Professor in the Department of Radiation Medicine and Applied Sciences. Her research is focused on radiogenomics for personalizing radiation therapy to improve outcomes.

Dr. Deichaite is widely published in numerous scientific journals. Dr. Deichaite received her Ph.D. from Princeton University, Master's degree from the Weizmann Institute, and BA from Hebrew University.



Ezra Cohen, MD, FRCPSC, FASCO

*Chief, Division of Hematology/Oncology
Department of Medicine, UC San Diego
Co-Director, San Diego Center for Precision Immunotherapy
Associate Director for Clinical Sciences,
UC San Diego Moores Cancer Center
Co-Leader, Solid Tumor Therapeutics Program
Co-Director, Hanna and Mark Gleiberman Head and Neck
Cancer Center*

Ezra Cohen, MD, is Chief of the Division of Hematology-Oncology, and co-Director of the San Diego Center for Precision Immunotherapy and an internationally renowned translational researcher. A physician-scientist, Dr. Cohen led an independently funded laboratory interested in mechanisms of action of novel therapeutics. He has made major contributions to targeted therapy. His recent National Institutes of Health-funded work in the study of epidermal growth factor receptor inhibitors in head and neck cancer has contributed to the understanding of the biology of this critical signaling network, integration of these agents into standard of care, and definition of mechanisms to overcome resistance. He recently served as chair of the NCI Head and Neck Cancer Steering Committee that oversees NCI-funded clinical research (including all NCI Cooperative Group trials) in this disease.

Dr. Cohen is Associate Director for Clinical Science and Co-Director Hanna and Mark Gleiberman Head and Neck Cancer Center. He brings his expertise and preeminent reputation in head and neck cancer research and patient care to solid tumor therapeutics. Among other roles, he is Co-Director, IEM Center for Engineering in Cancer and serves as a member of the Cancer Council, and the Cancer Center's Executive Committee.

Dr. Cohen recently served as editor-in-chief of Oral Oncology, the highest impact specialty journal in head and neck cancer and has recently chaired two Multidisciplinary Head and Neck Cancer Symposia—the largest international meeting of its kind—sponsored by the American Society for Radiation Oncology, the American Society of Clinical Oncology and the American Head and Neck Society. He has been the principal investigator on multiple studies of novel agents in head and neck cancer and other solid tumors in all phases of development including chemoprevention, phase I, II, and III trials. Dr. Cohen has a record of distinguished cancer research with over 200 peer-reviewed manuscripts and an h-index of 76 and has presented his research at national and international meetings. In addition, he has served as a grant reviewer for the NIH, American Association for Cancer Research, American Society of Clinical Oncology, and the Ontario Institute for Cancer Research.

Dr. Cohen completed residencies in Family Medicine at the University of Toronto and in Internal Medicine at Albert Einstein College of Medicine. He completed a Hematology/Oncology fellowship at the University of Chicago where he was named chief fellow. Prior to his arrival in San Diego, Dr. Cohen was Co-Director of the Head and Neck Cancer Program, Associate Director for Education and Program Director for the Hematology/Oncology Fellowship at the University of Chicago Comprehensive Cancer Center. A dedicated educator, Dr. Cohen also mentored and developed young faculty in his program.



J. Silvio Gutkind, PhD

*Distinguished Professor and Chair,
Department of Pharmacology, School of Medicine
Associate Director of Basic Science,
Moore's Cancer Center
UC San Diego*

Dr. Gutkind is a Distinguished Professor and Chair, Department of Pharmacology, School of Medicine, and Associate Director for Basic Science at the Moores Cancer Center, University of California San Diego. He received his Ph.D. in pharmacy and biochemistry from the University of Buenos Aires, Argentina. After his post-doctoral training at the NCI, he served as the Chief of the Oral and Pharyngeal Cancer Branch, NIDCR, NIH, since 1998 until his recruitment to UCSD in 2015.

His research team is exploiting the emerging information on dysregulated signaling circuitries and individual genomic and molecular alterations to develop new precision cancer therapies, and to identify novel multimodal strategies to enhance the response to cancer immunotherapies. Dr. Gutkind has led a multi institutional clinical trial establishing the benefits of treating oral cancer patients with mTOR inhibitors, and he is co-leading a new mTOR-targeting chemoprevention trial in oral premalignancy. His laboratory has launched a new effort exploring multimodal precision immunotherapy approaches for cancer prevention and treatment

His honors include the NIH Merit Award, the Elliot Osserman Award from the Israel Cancer Research Foundation, the Pharmaceutical Research and Manufacturers of America (PhRMA) Award, and the election as the Chair, Division of Molecular Pharmacology, ASPET. He was elected in 2019 to the National Academy of Medicine, recognizing his team's translational efforts in the area of cancer signaling. He has published over 500 research articles in some of the most prestigious journals. He has mentored many junior investigators, who are now playing leadership roles in multiple institutions in the United States and abroad.



Catriona Jamieson, MD, PhD

Professor of Medicine

Deputy Director, Moores Cancer Center

Koman Family Presidential Endowed Chair in Cancer Research

Chief, Division of Regenerative Medicine

Director, Sanford Stem Cell Clinical Center

Co-Leader, Hematologic Malignancies Program

Director, Stem Cell Research, Moores Cancer Center

UC San Diego

Catriona Jamieson, MD, Ph.D. is a leading physician-scientist who discovered missplicing, RNA hyper-editing, and splice isoform switching as mechanisms governing human cancer stem cell maintenance in selective niches. This pioneering cancer stem cell research has transformed therapies, including JAK2 and sonic hedgehog-inhibitor trials for myeloproliferative neoplasms and leukemia stem cell targeting. Her research and efforts lead to the 2019 FDA approval of fedratinib for the treatment of adult patients with intermediate-2 or high-risk primary or secondary Myelofibrosis. She also sent the first bioreactors with cancer organoids that detect activation of cancer stem cell properties in real-time into space on April 8, 2022, as part of the Integrated Space Stem Cell Orbital Research (ISSCOR) Program. The purpose is to identify biomarkers for early detection, and interventional leads and lay the groundwork for future cancer stem cell research in space. She is a Professor of Medicine, Chief of the Division of Regenerative Medicine, the Koman Family Presidential Endowed Chair in Cancer Research, Deputy Director of the Moores Cancer Center, and the Director of the Sanford Stem Cell Clinical Center at the University of California San Diego. Dr. Jaimeson received the 2017 MPN Hero's Award, the Moores Cancer Center Rell Sunn Award in 2020 (past awardees include Roger Tsien, Kary Mullis, Tony Hunter, Brian Druker, Carl June, J. Craig Venter), and the Top Doctor for the 10th consecutive year by Castle Connolly in 2021.



Thomas Kipps, MD, PhD

*Distinguished Professor of Medicine,
Evelyn and Edwin Tasch Chair in Cancer Research,
Director of the Center for Novel Therapeutics,
Deputy Director of Research Operations,
Moores Cancer Center
UC San Diego*

Thomas Kipps, MD, PhD, is Distinguished Professor of Medicine, Evelyn and Edwin Tasch Chair in Cancer Research, Director of the Center for Novel Therapeutics, and Deputy Director of Research Operations at the UC San Diego's Moores Cancer Center. Dr. Kipps is a two-time awardee of a Specialized Center of Research (SCOR) in Leukemia grant from the Leukemia and Lymphoma Society, a two-time awardee of the NIH MERIT Award, and principal investigator of the CLL Research Consortium (CRC), which directed inter-institutional research among the leading investigators in CLL from across the country and abroad. Dr. Kipps is a core member of the international workshop on CLL (iwCLL) and an awardee of the Rai/Binet medal for outstanding contributions to the field of leukemia research. Dr. Kipps is the current Chair of the NCI Developmental Therapeutics Study Section and Associate Editor for Leukemia. He has received continuous peer-reviewed, extra-mural funding for research throughout his career and maintained a high level of research productivity.




Scott Lippman, MD

*Director, Moores Cancer Center
Distinguished Professor of Medicine
Senior Associate Dean and Assistant Vice Chancellor, Cancer
Research and Care
UC San Diego*

Scott M. Lippman, MD, is Distinguished Professor of Medicine; Director, Moores Cancer Center (MCC); Senior Associate Dean and Associate Vice Chancellor (AVC) for Cancer Research and Care; and holds the Chugai Pharmaceutical Chair at UC San Diego. He currently serves as adjunct professor at the Salk Institute for Biological Studies, Sanford Burnham Prebys Medical Discovery Institute, and MD Anderson Cancer Center (MDACC). Prior to his recruitment to MCC in 2012, he was on faculty at MDACC for 24 years, including holding the Ellen F. Knisely and the Charles A. LeMaistre Distinguished endowed chairs; and

serving as Chair of the Departments of Clinical Cancer Prevention and Thoracic/Head and Neck Medical Oncology, respectively, for the 16 years preceding his move to MCC. He has led translational, transdisciplinary programs, notably as PI of an NCI Head and Neck (HN) Cancer SPORE, 2 P01s; and currently leads a Stand Up to Cancer (SU2C) Interception Dream Team award. His research interests include precancer biology, invasive-disease transition and cancer interception, with continuous NCI funding as a PI since 1990. Dr. Lippman was senior author of the primary report of the Erlotinib Prevention of Oral Cancer (EPOC) randomized controlled trial (RCT) (JAMA Oncol, 2016) and follow-on reports discovering genetic drivers of immune evasion in oral precancer-invasive transition; PI of a recently reported NCI N01 trial (JCI Insights, 2021); and current MPI of an NCI R01 on oral cancer signaling/prevention. He has published preliminary findings of PD-L1 amplification and high mutational burden (in microsatellite-stable tumors) as tissue-agnostic predictive genomic biomarkers of response to immune-checkpoint blockade (ICB) in solid tumors (JAMA Oncol, 2018; Cancer Immunol Res, 2019). Most recently, he has been studying genomic predictors of immune oncology [IO] and immune-checkpoint therapy [ICT] efficacy (germline, manuscript in prep) and was senior author of a pivotal report of genomic copy-number alteration influence on immune microenvironment/evasion in the oral precancer-invasive cancer transition and the evolution of HPV-negative (HPV-) head and neck tumorigenesis; and most importantly, standard-of-care changing discovery, extensively characterizing and validating a the role of chromosome 9p21.3-centered copy-number loss as an essential, profound genomic driver of immune-cold tumor microenvironments in HPV- head and neck cancer (HNSC), and anti-PD-1 checkpoint-inhibitor resistance (William et al., PNAS 2021), which has been confirmed by an independent group, and CAP/CLIA validated for standard use in the clinic within six months of the primary publication to help guide treatment decisions in recurrent/metastatic HPV- head and neck cancer (HNSC); and has important implications for therapeutic, early-detection and prevention research. He has been an invited speaker at national and international symposia and conferences, including in 2021—NCI Molecular and Cellular Characterization of Screen-Detected Lesions (MCL) Consortium, City of Hope Presidential Lectureship, 22nd Annual OSUCCC - James Scientific Meeting (ASM), FDA Mini-symposium on Cancer Prevention, 35th Aspen Cancer Conference, National Press Club presentation for National Foundation for Cancer Research, and the 5th International Cancer Symposium organized (February, 2022) in Lyon, France. He served on the board of directors for the American Association for Cancer Research (AACR), Association of American Cancer Institutes (AACI; and program committee chair), and the Worldwide Innovative Networking (WIN) consortium; and was founding Editor-in-Chief of the AACR journal Cancer Prevention Research, and appointed chair of the AACR cancer prevention committee by then-president Liz Blackburn. Dr. Lippman was a member of the NCI Board of Scientific Advisors Cancer Center Directors Working Group and the NIH Scientific Review Group: NCI Subcommittee A – Cancer Centers, 2016-2019. He held prior positions as: member of the FDA Oncologic Drugs Advisory Committee (ODAC), chair of the NCI CDP Prevention Study Section, member of the NCI Clinical Trials and Translational Research Advisory Committee (CTAC), chair of the SWOG cancer control research committee (and member of Scientific Advisory Board, SAB), and chair of the American Society of Clinical Oncology (ASCO) cancer prevention committee. He has published over 450 peer-reviewed primary research articles, received numerous ASCO, AACR, ACS, and other (e.g., team-science) awards and is an elected member of the Association of American Physicians (AAP) and the National Academies of Sciences, Engineering, and Medicine National Cancer Policy Forum. He was chair of the 2017 NCI Pre-Cancer Genome Atlas (PCGA) think tank; and member of the 2021 Pre-Cancer Atlas (PCA) Human Tumor Atlas Network (HTAN) and 2021 AIM-HI Women's Venture Competition (WVC) review panels (the AIM-HI Accelerator Fund's WVC is a first-of-its-kind program that provides funding, coaching and networking opportunities to women-led oncology start-ups). He has a strong track record, commitment, and passion to train the next generation of scientists and doctors (including serving as member of several PhD thesis committees), and to promote equity, diversity and inclusion in his current/ongoing roles as NCI Comprehensive MCC Director, AVC at UCSD Health System, and nationally in AIM-HI WVC.



Steven Garfin, MD

*Interim Vice Chancellor, Health Sciences
Interim Dean, School of Medicine
UC San Diego*

Steven Garfin, MD, is Vice Chancellor of Health Sciences and interim dean of the University of California San Diego School of Medicine. In this role, he directs the school's educational mission, including the evolution of its curriculum, and provides oversight for all academic and clinical departments and research units. He has a leadership role in all School of Medicine councils and collaborates with medical school deans across the five University of California medical campuses.

An internationally recognized leader in orthopedic surgery, Dr. Garfin joined the UC San Diego School of Medicine faculty in 1981 and has served as chair of the Department of Orthopaedic Surgery since 1997. Under his oversight, the department received more than \$21 million in annual grant funding and ranked nationally for research output. Dr. Garfin is well established as a forward-thinking leader, having been involved in designing and assessing surgical techniques and instrumentation to treat spinal disorders. At UC San Diego Health, he was the first to articulate the need for a world-class ambulatory building to support Jacobs Medical Center, a vision that resulted in the opening of the Koman Family Outpatient Pavilion.

In his clinical practice, Dr. Garfin specializes in complex reconstructive spine surgery, but also provides treatment for all types of spine conditions, including adult scoliosis, disc herniation and spinal cord injury. He has received many awards for teaching, research and clinical care, including work that has contributed to current international standards for spine surgery. Dr. Garfin earned his medical degree at the University of Minnesota and completed both an internship in surgery and an orthopedic surgery residency at UC San Diego School of Medicine. He completed a fellowship in adult spine disorders at Pennsylvania Hospital.

He is a member or has served in leadership roles for several national and international spine societies, including the American Academy of Orthopaedic Surgeons, American Orthopaedic Association, International Society for the Study of the Lumbar Spine (ISSLS), the Orthopaedic Research Society, and the Lumbar Spine Research Society. He is a past president of the North American Spine Society (NASS), the International Society for the Advancement of Spine Surgery, and the Cervical Spine Research Society (CSRS). Dr. Garfin also serves on the Executive Governing Board for UC San Diego Health. Among his many achievements, Dr. Garfin was named one of the top 28 surgeons in the U.S. by Orthopedics This Week in 2012. In 2013, he was honored with a lifetime achievement award by the International Society for the Study of Lumbar Spine, and by NASS with both the Wiltse Award and the Selby Award.

Dr. Garfin has edited 21 books, authored more than 145 book chapters, and published over 300 peer-reviewed articles. He is deputy editor of the Spine Journal, which has the highest impact factor of orthopedic specialty journals, and reviewer for a number of other orthopedic and spine peer-reviewed journals. His research awards include two Volvo Awards from ISSLS, multiple awards from NASS and CSRS, and the Orthopaedic Research Society New Investigator Recognition Award. He was the director of all American Academy of Orthopaedic Surgeons spine courses from 1990 to 1998, including the spine section of their instructional course lectures at annual meetings. He has also led or co-led a number of research grants supported by the National Institutes of Health, Department of Veterans Affairs and industry. Additionally, Dr. Garfin has served as the national principal investigator for a number of clinical trials for innovative new technologies in Phase I testing or through clinical trials leading to FDA and Medicare approvals.



Kristen M. Hege, MD

*Senior Vice President,
Early Clinical Development
Hematology/Oncology and Cell Therapy
Bristol Myers-Squibb*

At BMS, Dr. Hege is responsible for advancing a pipeline of small molecules, biologics and cell therapies from first-in-human studies through clinical proof-of-concept. In addition, she led the bluebird-partnered BCMA CART cell program (Abecma) in multiple myeloma from inception through FDA approval. Prior to BMS she held a similar role at Celgene as well as executive roles in biotech at Cell Genesys, Cellerant, and Theraclone.

In addition to her work at BMS, Dr. Hege is a Clinical Professor of Medicine at UCSF where she sees patients with blood cancers weekly. She also serves on the Board of Directors of Mersana Therapeutics and Graphite Bio and served on the Board of the Society for Immunotherapy of Cancer for a 3-year term from 2016-2019.

Dr. Hege received her M.D. at UCSF and internal medicine and hematology/oncology subspecialty training at Harvard and UCSF, respectively. In 2015 she was recognized by Fierce Biotech as one of the top 12 women in Biopharma, in 2019 by the Healthcare Businesswomen's Association as a "Luminary", and in 2021 by San Francisco Business Times as one of the most influential women in Bay Area business and by PharmVOICE as 100 of the most inspiring people. Her career path and long history with CAR T cell development was featured as one of 25 physicians and scientists recognized as part of the 25th anniversary celebration of Nature Medicine.



Carl H. June, MD

*Richard W. Vague Professor in Immunotherapy,
Department of Pathology and Laboratory Medicine,
Director, Center for Cellular Immunotherapies,
Perelman School of Medicine,
Director, Parker Institute for Cancer Immunotherapy,
University of Pennsylvania*

Carl June is the Richard W. Vague Professor in Immunotherapy in the Department of Pathology and Laboratory Medicine. He is currently Director of the Center for Cellular Immunotherapies at the Perelman School of Medicine, and Director of the Parker Institute for Cancer Immunotherapy at the University of Pennsylvania. He is a graduate of the Naval Academy in Annapolis, and Baylor College of Medicine in Houston, 1979. He had graduate training in Immunology and malaria with Dr. Paul-Henri Lambert at the World Health Organization, Geneva, Switzerland from 1978-79, and post-doctoral training in transplantation biology with E. Donnell Thomas and John Hansen at the Fred Hutchinson Cancer Research Center in Seattle from 1983 - 1986. He is board certified in Internal Medicine and Medical Oncology. He maintains a research laboratory that studies various mechanisms of lymphocyte activation that relate to immune tolerance and adoptive immunotherapy for cancer and chronic infection. In 2011, his research team published findings detailing a new therapy in which patients with refractory and relapsed chronic lymphocytic leukemia were treated with genetically engineered versions of their own T cells. The treatment has also now also been used with promising results to treat children with refractory acute lymphoblastic leukemia. He has published more than 350 manuscripts and is the recipient of numerous prizes and honors, including election to the Institute of Medicine in 2012 and the American Academy of Arts and Sciences in 2014, the William B Coley award, the Richard V Smalley Memorial Award from the Society for Immunotherapy of Cancer, the AACR-CRI Lloyd J. Old Award in Cancer Immunology, the Philadelphia Award in 2012, the Taubman Prize for Excellence in Translational Medical Science in 2014 (shared w S. Grupp, B. Levine, D. Porter), the Paul Ehrlich and Ludwig Darmstaedter Prize (shared w J. Allison), the Novartis Prize in Immunology (shared w Z. Eshaar and S. Rosenberg), the Karl Landsteiner Memorial award, the Debrecen Award and a lifetime achievement award from the Leukemia and Lymphoma Society.



Fotis Asimakopoulos, MB BChir, PhD

*Associate Professor
Moore's Cancer Center
UC San Diego*

Fotis completed his MD/PhD at the University of Cambridge in the UK, working with Tony Green on mapping 20q deletions associated with pre-leukemias. He then spent two (in his own words, “unforgettable”) years in Jerusalem working with Dina Ben Yehuda as a Golda Meir Fellow on mechanisms underlying CML clonal evolution.

After residency at Brigham and Women’s Hospital in Boston and oncology fellowship at Memorial Sloan-Kettering Cancer Center in New York, he joined Nobel prize laureate Harold Varmus’ group at MSK. In Harold’s lab, he began his work to generate a RAS-driven model for myeloma, a goal that eventually came to fruition several years later, with the publication of the VQ model (in collaboration with Jing Zhang’s group at UW-Madison as well as Marta Chesi and Leif Bergsagel at Mayo).

In 2010, he became an Assistant Professor and later a tenured Associate Professor at UW-Madison. The Asimakopoulos lab moved to UCSD and sunny San Diego in 2019.



Joseph Califano, MD

Physician in Chief, Moores Cancer Center

Director, Hanna and Mark Gleiberman Head and Neck Cancer Center

Co-Leader, Structural and Functional Genomics, Moores Cancer Center

Professor and Iris and Matthew Strauss Chancellor's Endowed Chair in Head and Neck Surgery

Department of Otolaryngology-Head and Neck Surgery

UC San Diego

Joseph A. Califano, III, MD, is a board-certified otolaryngologist. He is an internationally recognized head and neck surgeon who specializes in tumors of the oral cavity (mouth), salivary glands, pharynx (throat), larynx (voice box), sinuses, thyroid, and skull base. Dr. Califano has expertise in minimally invasive surgical techniques, including endoscopic laser and robotic surgery, to help best preserve function and appearance in his patients. He has an interest in HPV-related cancers of the throat, as well as premalignant conditions of the upper aero digestive tract.

His other areas of investigation include integrative network-based molecular analysis of head and neck tumors; detection of recurrent and occult primary cancer within blood and saliva using molecular biologic techniques; and defining the underlying biology of head and neck cancers.

A frequent speaker at national and international meetings, Dr. Califano has coauthored numerous textbooks and book chapters and over 230 peer-reviewed articles related to both clinical and scientific aspects of cancer. His work has appeared in *Nature*, *Oral Oncology* and *Clinical Cancer Research*, among others. He reviews and serves on the editorial board for a variety of medical journals, including *Oral Oncology*, the most respected specialty journal in head and neck cancer.

In his free time, Dr. Califano enjoys rock climbing, and is learning how to surf. He and his wife, Beth, have two children.



Brendan Eckelman, PhD

Founder

EVP Chief Scientific Officer

INHIBRx

Brendan Eckelman Ph.D. is a co-founder and the Chief Scientific Officer of Inhibrx, a clinical stage biotherapeutics company. He heads research, overseeing key functional areas spanning early discovery, protein engineering, biotherapeutic development and translational efforts. He has pioneered the innovative suite of therapeutic formats that enable Inhibrx's differentiated pipeline. He is deeply involved with many operational facets of Inhibrx including business development, partnering, intellectual property and clinical strategy. Brendan spearheaded the formation of Phylaxis Biosciences, an Inhibrx joint venture focused on eosinophilic and mast cell disorders and currently serves on its Scientific Advisory Board. He is an Entrepreneur in Residence for the Office of Innovation and Commercialization at the University of California, San Diego, where he advises founders and start-ups on venture creation and strategy. Prior to Inhibrx, Brendan was a Research Investigator in the biotherapeutics group at the Genomics Institute of the Novartis Research Foundation. He conducted his graduate research at the Sanford-Burnham-Prebys Medical Discovery Institute and received Ph.D. in Molecular Pathology from the University of California, San Diego School of Medicine. He received his B.S. in Molecular Biology and his M.S. in Biology from UCSD.



Ayman El-Guindy, PhD

*Chief Scientific Officer
Viracta Therapeutics*


Ayman El-Guindy, Ph.D., has over 23 years of experience studying the role of viruses in cancer and spent the last decade as a faculty member at Yale University School of Medicine, most recently as an Associate Professor in the Department of Pediatrics, Section of Infectious Disease, and the Department of Pathology. At Yale, Dr. Elguindy ran a laboratory focused on the involvement of herpesviruses in the etiology and prognosis of cancer. His group studied the fundamental role of herpesvirus protein kinases in viral pathogenesis and as potential targets for drug development. Additionally, he made seminal contributions to the understanding of oncogenic herpesvirus reactivation from latent to lytic state, the process of viral DNA replication, role of virally encoded cytokines in mediating cell proliferation, and temporal regulation of viral gene expression during infection. He has been awarded numerous grants from organizations such as the American Cancer Society and the National Cancer Institute to study the mechanisms regulating EBV gene expression and the role of viruses in cancer as both a Principal and Co-Investigator. Dr. Elguindy has authored over two dozen peer-reviewed publications and serves in editorial roles at the scientific journals *Pathogens* and *Frontiers in Microbiology*. He also serves as a reviewer for multiple journals including *PLoS Pathogens* and the *Journal of Virology*. He received his Ph.D. and M.Ph. in Molecular Biophysics and Biochemistry from Yale University.



Ananda Goldrath, PhD

*Tata Chancellor's Professor
Division of Biological Sciences
Molecular Biology Section
UC San Diego*

Ananda Goldrath is a Tata Chancellor's Professor in the Division of Biological Sciences and former Chair of the Molecular Biology Section. Her work as an Immunologist has contributed to the understanding transcriptional networks that govern the formation and maintenance of long-lived protective immunity. Professor Goldrath's research explores the mechanistic basis underlying memory T cell differentiation by driving or suppressing target genes essential for differentiation of protective T cell subsets, by regulating metabolic pathway usage, or by controlling access to and survival in tissues. Using this information, it has proved possible to beneficially manipulate the immune system to eliminate infection and malignancies. Professor Goldrath is Pew Scholar and Leukemia and Lymphoma Society Fellow and is a member of the Immunological Genome Project, the Leadership Council of the Program in Immunology and Scientific Advisory Committee of the San Diego Center for Precision Immunotherapy at UCSD.



Theresa Guo, MD

*Assistant Professor of Surgery
Division of Otolaryngology
Gleiberman Head & Neck Cancer Center
Moores Cancer Center
UC San Diego*

Theresa Guo, MD, is a head and neck surgeon and Assistant Professor at the University of California, San Diego. She is part of the Gleiberman Head & Neck Cancer Center and Moores Cancer Center. In addition to patient care, she is also engaged in research that seeks to deliver precision cancer care. Her research uses computational biology to study complex post-transcriptional genomic changes that occur in head and neck tumors. Dr. Guo completed a fellowship in head and neck surgical oncology at University of Texas MD Anderson Cancer Center in Houston. She completed her residency training in otolaryngology at The Johns Hopkins Hospital, Baltimore, Maryland. Dr. Guo earned her medical degree at Cleveland Clinic Lerner College of Medicine, a program of Case Western Reserve University School of Medicine



Shweta Joshi, PhD

*Assistant Professor of Pediatrics
Moores Cancer Center
UC San Diego*

Shweta Joshi is an Assistant Professor of Pediatrics at the Moores Cancer Center, University of California, San Diego. Dr. Joshi received her Ph.D. in Biochemistry from Central Drug Research Institute, Lucknow, India, and completed her postdoctoral training at the University of California, San Diego. Her research has focused on understanding the cellular and molecular mechanisms that regulate the recruitment and activation of immunosuppressive myeloid cells in solid tumors and the subsequent regulation those cells exert on the evolving tumor microenvironment. Dr. Joshi has investigated novel, innovative approaches to convert pro-tumor macrophages into anti-tumor macrophages and has also discovered novel targeted agents that have been translated into early-phase clinical trials for the treatment of cancer patients. Her lab has recently identified a novel macrophage autonomous pathway involving Rac2 and Syk downstream of the provisional integrins $\alpha 4\beta 1$ that controls immunosuppressive macrophage polarization in tumor growth and metastasis. Her current research has demonstrated that Syk inhibitors are valuable therapeutic agents for solid tumor therapy.

Dr. Joshi was also involved in the preclinical development of targeted therapies for pediatric malignancies, including neuroblastoma. She has identified that dual inhibition of two key signaling pathways by a single molecule (SF1126/SF2523) can block tumor growth and metastasis effectively in various tumor models, with no toxicity. These findings led to a phase 1 clinical trial of SF1126 in relapsed or refractory neuroblastoma.



Dan Kaufman, MD, PhD

*Professor of Medicine
Division of Regenerative Medicine
Director of Cell Therapy
UC San Diego*

Dr. Kaufman is a Professor in Department of Medicine, Division of Regenerative Medicine and Director of the Cell Therapy program at the University of California-San Diego (UCSD).

Following undergraduate studies at Stanford University, he completed a combined MD/PhD program at Mayo Clinic and a clinical residency and fellowship in internal medicine and hematology at the University of Wisconsin-Madison.

Dr. Kaufman also provides clinical care for patients with hematological malignancies, with special interest in blood and marrow transplantation (BMT) and immune therapies.

The Kaufman laboratory uses human pluripotent stem cells to understand the development of blood cells. The aim is to use human embryonic stem cells (hESCs) and human induced pluripotent stem cells (iPSCs) as a resource to produce blood and immune cells (mainly natural killer cells) for new clinical applications for treatment of relapsed/refractory cancers — both hematologic malignancies and solid tumors. The lab is also working on production of blood cells (monocytes and macrophages) that can be used for tissue repair and regeneration.



Alexis Komor, PhD

Assistant Professor

Department of Chemistry and Biochemistry

UC San Diego

Alexis received her B. S. degree in chemistry from the University of California, Berkeley in December of 2008. She then joined the lab of Jacqueline K. Barton at the California Institute of Technology for her doctoral studies. While at Caltech, she worked as an NSF Graduate Research Fellow on the design, synthesis, and study of DNA mismatch-binding metal complexes and received her Ph.D. in 2014. She pursued postdoctoral work as a Ruth L. Kirschstein NIH Postdoctoral Fellow in the laboratory of David R. Liu, where she developed base editing, a new approach to genome editing that enables the direct, irreversible chemical conversion of one target DNA base into another in a programmable manner, without requiring double-stranded DNA backbone cleavage. Alexis joined the Department of Chemistry and Biochemistry at the University of California at San Diego in 2017, where her lab develops and applies new precision genome editing techniques to the functional genomics field. Alexis's contributions in teaching, mentoring, and research have been recognized through many awards, including a Young Investigator Award by the International Society for Transgenic Technologies, the Cottrell Scholar Award by the Research Corporation for Science Advancement, the inaugural Rosalind Franklin Medal by the Rosalind Franklin Society and the Genome Writers Guild, an Outstanding Mentor Award by the UCSD Undergraduate Research Hub, the "Talented 12" recognition by C&EN News, an NSF Faculty Early Career Development (CAREER) award, an NIH early stage investigator Maximizing Investigators' Research Award (MIRA), and a "40 under 40" recognition in healthcare by Fortune Magazine.



Peter Olson, PhD

*Executive Director of Research
Mirati Therapeutics*

Pete Olson is Executive Director of Research at Mirati Therapeutics, a clinical-stage company focused on developing innovative, targeted therapies for the treatment of cancer. Mirati is developing a covalent KRAS G12C inhibitor, a spectrum-selective tyrosine kinase inhibitor, an MTA-cooperative PRMT5 inhibitor, along with a pipeline of preclinical programs. Prior to joining Mirati, he was a Senior Group Leader in the Oncology Research Unit at Pfizer.

Pete received his Ph.D. from UCSD and conducted his thesis work in Ron Evans' lab at The Salk Institute studying the role of nuclear fatty acid receptors in metabolic disease and cancer. He did his postdoc in Doug Hanahan's lab at UCSF where he used mouse models to interrogate mechanisms of tumorigenesis and as a platform to test experimental therapeutics.



Charles Theuer, MD, PhD

*President and CEO
TRACON Pharmaceuticals*

Dr. Theuer has served as our President, Chief Executive Officer and a member of the Board of Directors of TRACON Pharmaceuticals (NASDAQ: TCON) since July 2006. From 2004 to 2006, Dr. Theuer was the Chief Medical Officer and Vice President of Clinical Development at TargeGen, Inc., a biotechnology company, where he led the development of small molecule kinase inhibitors in oncology, ophthalmology and cardiovascular disease. Prior to joining TargeGen, Inc., Dr. Theuer was Director of Clinical Oncology at Pfizer, Inc., a pharmaceutical corporation, from 2003 to 2004. At Pfizer, Dr. Theuer led the clinical development of Sutent® in kidney cancer; Sutent® was approved by the U.S. Food and Drug Administration in 2006 for the treatment of advanced kidney cancer. Dr. Theuer has also held senior positions at IDEC Pharmaceuticals Corp. from 2002 to 2003 and at the National Cancer Institute from 1991 to 1993. In addition, he has held academic positions at the University of California, Irvine, where he was Assistant Professor in the Division of Surgical Oncology and Department of Medicine. Dr. Theuer received a B.S. from the Massachusetts Institute of Technology, an M.D. from the University of California, San Francisco, and a Ph.D. from the University of California, Irvine. He completed a general surgery residency program at Harbor-UCLA Medical Center and was board certified in general surgery in 1997. Dr. Theuer's previous research involved immunotoxin and cancer vaccine development, translational work in cancer patients, and gastrointestinal cancer epidemiology. He serves as Board Director for Oncternal Therapeutics (NASDAQ: ONCT) and 4D Molecular Therapeutics (NASDAQ: FDMT).



Ben Thompson, MD, PhD

*Medical Director, Clinical Development
Xencor*

Ben received his MD and PhD in Immunology from The University of Chicago's Medical Scientist Training Program. His dissertation, under Dr. Iannis Aifantis, described the roles of the Fbw7 ubiquitin ligase in normal and leukemic hematopoiesis. Ben further studied cell-cycle regulation and leukemogenesis as a postdoctoral fellow at Northwestern University in the laboratory of Dr. John Crispino, before joining Halozyme Therapeutics in San Diego, where he worked in both preclinical and clinical immuno-oncology development. Since joining Xencor in 2019, he has worked on the early-phase clinical development of XmAb841 (CTLA4 x LAG3), XmAb104 (PD1 x ICOS), and XmAb808 (CD28 x B7H3).



Robert Wild, PhD

*Chief Scientific Officer
Dracen Pharmaceuticals*

Dr. Wild joined Dracen Pharmaceuticals in 2017 as one of the founding executives and Chief Scientific Officer (CSO). He is responsible for all discovery, preclinical development and translational research efforts of Dracen's therapeutic pipeline and leads scientific strategy. Dr. Wild is a seasoned R&D executive with 20+ years of broad experience in drug discovery and development, spanning both small molecules and biologics. Throughout his career, Dr. Wild has contributed to the advancement of numerous clinical development candidates, including five FDA-approved oncology therapeutics (sunitinib, cetuximab, dasatinib, erlotinib and entrectinib). Before Dracen Pharmaceuticals, Dr. Wild was an independent consultant to biotech, pharma and venture capital companies. Prior to that, he served in various leadership roles including Chief Scientific Officer and Senior Vice President of Research at Ignyta, Inc. (now member of the Roche Group), Chief Scientific Officer Oncology Research at Eli Lilly & Company, Senior Director at OSI Pharmaceuticals (now a wholly owned subsidiary of Astellas Pharma), Senior Research Investigator at Bristol-Myers Squibb and Scientist at SUGEN, Inc. (acquired by Pfizer). Dr. Wild is a native of Germany and received his BS in Biochemistry and PhD in Pharmacology from the University of Minnesota, Minneapolis.

Steve Worland, PhD

*President and CEO
eFFECTOR Therapeutics*



Dr. Steve Worland is currently President and CEO and a director of eFFECTOR Therapeutics (NASDAQ:EFTR), which he co-founded in 2012. Previously, Dr. Worland was CEO of Anadys Pharmaceuticals, a biopharmaceutical company which discovered and developed treatments for hepatitis C and cancer, until its acquisition by Roche in 2011. Prior to being named CEO at Anadys, he was CSO and President, Pharmaceuticals. Dr. Worland began his career at Agouron Pharmaceuticals and remained with the company through its successful commercialization of an HIV protease inhibitor and successive acquisitions by Warner-Lambert and Pfizer. During this period, Dr. Worland held various positions, including Vice President, Director of Molecular Biology and Biochemistry. Dr. Worland was an NIH postdoctoral fellow in molecular biology at Harvard University, received a Ph.D. in chemistry at University of California, Berkeley and a B.S. with Highest Honors in Biological Chemistry from the University of Michigan.



Jing Yang, PhD

*Professor of Pharmacology and Pediatrics
Moores Cancer Center
UC San Diego*

Dr. Jing Yang is a Professor of Pharmacology and Pediatrics at University of California, San Diego. She obtained her PhD in Molecular Cancer Biology with Dr. Sally Kornbluth at Duke University in 1999. In 2000, Dr. Yang became a Damon Runyon Cancer Research Foundation postdoctoral fellow with Dr. Robert Weinberg at Whitehead Institute for Biomedical Research and identified a critical role of the Twist1 transcription factor and Epithelial-Mesenchymal Transition (EMT) in tumor metastasis. Dr. Yang joined the faculty of University of California, San Diego as an Assistant Professor in 2006 and was promoted to Associate Professor with tenure in 2012 and professor in 2016.

Dr. Yang's research focuses on understanding the molecular basis of tumor metastasis. Her laboratory combines cell and molecular biology tools, mouse tumor models, 3D organoids culture, functional genomics, and 2D/3D imaging techniques to uncover the genes and the signaling pathways responsible for tumor metastasis. Her group has identified invadopodia-mediated extracellular matrix degradation, matrix stiffening, and epithelial polarity as being critical regulatory mechanisms of EMT and tumor metastasis and continues to address the dynamic involvement of these programs in metastasis. Dr. Yang's achievements have been recognized by many awards, including NIH Director's New Innovators Award, American Cancer Society Research Scholar, Kimmel Scholar award, Metastasis Research Society Young investigator award, and the John Abel award from ASPET society.